2025
conference-paper
OpenAlex
Mojtaba Shafiekhani, T. Kluge, Ben Wilhelm-Feldbusch, Patrick Hucker et autres
Motivation: Tools for cross-platform open-source pulse sequence development have recently gained substantial traction within the MRI community. An important ingredient thereof is the set of scanner-specific "driver" or "interpreter" software modules, which currently have to be compiled and tested for every scanner …
Accès ouvert
2024
article
OpenAlex
Daniel J. Elsner, Christoph Köppl, Maximilian Kogler, Patrick Scheidl et autres
Accès ouvert
2024
article
OpenAlex
Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe et autres
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This study aimed to identify …
at, it, us, sg, sa
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jennifer Krummeich, Laura De Nardi, Cosima Caliendo, Dominik F. Aschauer et autres
Abstract Little is known about the influence of (impaired) neurodevelopment on cognitive aging. We here used a mouse model for tuberous sclerosis (TS) carrying a heterozygous deletion of the Tsc2 gene. Loss of Tsc2 function leads to mTOR hyperactivity in mice and …
de, at
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Elisabetta Indelicato, Klaus Faserl, Matthias Amprosi, Wolfgang Nachbauer et autres
Friedreich’s ataxia (FRDA) is a severe multisystemic disorder caused by a deficiency of the mitochondrial protein frataxin. While some aspects of FRDA pathology are developmental, the causes underlying the steady progression are unclear. The inaccessibility of key affected tissues to sampling is …
at
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe et autres
Abstract Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL pro /M pro ) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to …
at, it, us, ru, sg
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe et autres
Topology, trajectory and config files for each case presented in the publication.
2022
article
OpenAlex
Monika Cserjan‐Puschmann, Christoph Köppl, Nico Lingg, Rainer Schneider et autres
at
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Nico Lingg, Christina Kröß, Petra Engele, Christoph Öhlknecht et autres
Fusion protein technologies improve the expression and purification of recombinant proteins, but the removal of the tags involved requires specific proteases. The circularly permuted caspase-2 (cpCasp2) with its specific cleavage site, efficiently generates the untagged protein. While cleavage with cpCasp2 is possible …
at
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Christoph Köppl, Nico Lingg, Andreas M. Fischer, Christina Kröß et autres
are widely used but may also be associated with negative consequences. Although commonly employed solubility tags have a positive influence on titers, their large molecular mass inherently results in stochiometric losses of product yield. Furthermore, the introduction of affinity tags, especially the …
at
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Christina Kröß, Petra Engele, Bernhard Sprenger, Andreas M. Fischer et autres
Proteases serve as important tools in biotechnology and as valuable drugs or drug targets. Efficient protein engineering methods to study and modulate protease properties are thus of great interest for a plethora of applications. We established PROFICS (PRotease Optimization via Fusion-Inhibited Carbamoyltransferase-based …
at
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Alexander Mödlhammer, Sandra Pfurtscheller, Andreas Feichtner, Markus Hartl et autres
The c-Myc protein (MYC) is a transcription factor with strong oncogenic potential controlling fundamental cellular processes. In most human tumors, MYC is overexpressed by enhanced transcriptional activation, gene amplification, chromosomal rearrangements, or increased protein stabilization. To pharmacologically suppress oncogenic MYC functions, multiple …
at
(code pays fourni par la source)